[Eye and Behçet's disease].
Posterior uveitis is the most severe manifestation of ocular Behçet's disease, as it can lead to residual permanent damage. However, a better use of corticosteroid and immunosuppressive therapy in a multidisciplinary context has dramatically improved the overall visual prognosis and bilateral blindness is now rare.
Binisti
P
P
Service d'ophtalmologie Hôpital Cochin, Paris.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D003078:Colchicine / Q000627:therapeutic use; D003937:Diagnosis, Differential; D005128:Eye Diseases / Q000175:diagnosis / Q000209:etiology*; D005260:Female; D005451:Fluorescein Angiography; D006074:Gout Suppressants / Q000627:therapeutic use; D015235:HLA-B Antigens / Q000276:immunology; D059949:HLA-B51 Antigen; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D011379:Prognosis; D012008:Recurrence; D014606:Uveitis, Anterior / Q000175:diagnosis / Q000209:etiology; D015866:Uveitis, Posterior / Q000175:diagnosis / Q000209:etiology
D000305:Adrenal Cortex Hormones; D006074:Gout Suppressants; D015235:HLA-B Antigens; D059949:HLA-B51 Antigen; D007166:Immunosuppressive Agents; D003078:Colchicine